Dear Ms. Overstreet:

I am interested in being considered for the vacancy on the Glynn Brunswick Memorial Hospital Authority. Per the instructions with the vacancy announcement, I attached a copy of my vita to the letter.

I am an economist with a specialty in health care economics. I have worked on competition, regulation, contract, and tax issues in health care during my career in academic, federal government, and private sector positions. I have written articles on health care issues and testified in major health care litigations.

I have owned a home on Jekyll Island since 1993.

Please let me know if you need additional information.

Sincerely,

Richard P. Rozek, Ph.D.

RICHARD P. ROZEK, PH.D.

CONTACT INFORMATION Redacted Jekyll Island, GA 31527 Phone: 912 Redacted Redacted gmail.com

BACKGROUND

Dr. Rozek received a B.A. degree in Mathematics with honors from the College of St. Thomas, a M.A. degree in Mathematics from the University of Minnesota, and M.A. and Ph.D. degrees in Economics from the University of Iowa.

Dr. Rozek began his professional career as an Assistant Professor at the University of Pittsburgh where he taught courses in industrial organization, mathematical economics, and microeconomic theory. Dr. Rozek then worked for over six years in the Bureau of Economics at the Federal Trade Commission in a series of senior staff positions including Deputy Assistant Director for Antitrust. While at the FTC, Dr. Rozek evaluated antitrust and regulatory issues in electric and gas utilities, oil pipelines, soft drinks, for-profit and nonprofit hospitals, motion pictures, pharmaceuticals, and information industries. For two years, Dr. Rozek worked as the economist at the Pharmaceutical Manufacturers Association (now PhRMA). He conducted research on issues such as the cost to develop a new pharmaceutical, pharmaceutical industry profitability, benefits and costs of intellectual property protection, productivity of R&D personnel in the pharmaceutical industry, and reform of the health care reimbursement system.

Since 1987, Dr. Rozek has worked on projects in the antitrust/health, intellectual property, energy, and telecommunications practices at NERA Economic Consulting. Dr. Rozek has participated in the design of bidding processes for power generation markets and analysis of hospital rate regulation schemes. He has addressed economic issues in industries such as agricultural chemicals, automobiles, cellular telephone service, convenience food, electric equipment, electric utilities, hospitals, medical devices, newspapers, pharmaceuticals, and professional services. He has worked for plaintiffs and defendants in antitrust, contract dispute, patent infringement, personal injury, and libel cases. Dr. Rozek has authored public policy studies and valued intangible and tangible property for tax and other business purposes.

Dr. Rozek's articles have appeared in Applied Economics, Contemporary Policy Issues, Energy Journal, Economics Letters, Journal of Economics, Journal of World Intellectual Property, Mathematical Modelling, Metroeconomica, Research Policy, and Tax Notes International. He has been a referee for several professional journals and is a member of the American Economic Association and the National Association for Business Economics.

- 2 - RICHARD P. ROZEK

EDUCATION

UNIVERSITY OF IOWA Ph.D., Economics, 1976 M.A., Economics, 1974

UNIVERSITY OF MINNESOTA M.A., Mathematics, 1971

COLLEGE OF ST. THOMAS B.A., Mathematics, 1969 (cum laude)

EMPLOYMENT

NERA ECONOMIC CONSULTING, Washington, DC 2012- Special Consultant 2000-2012 Senior Vice President 1991-2000 Vice President 1987-1991 Senior Consultant Worked on projects involving regulated industries including design of bidding processes for acquiring power and allocating spectrum, and analysis of hospital rate regulation schemes; competition analyses in industries such as convenience food, electric equipment, electric utilities, hospitals, newspapers, pharmaceuticals, telecommunications and professional services; damage estimates in antitrust, contract dispute, patent infringement, personal injury and libel cases; compensation issues in professional sports; public policy studies in the pharmaceutical industry (intellectual property protection, parallel trade and pricing); and transfer pricing studies for consumer product, pharmaceutical and medical device firms.

PHARMACEUTICAL MANUFACTURERS ASSOCIATION, Washington, DC 1985-1987 Senior Analyst, Economics Analyzed issues affecting the research based pharmaceutical industry including intellectual property protection, costs and benefits of pharmaceutical therapies, the cost to develop a new pharmaceutical product, industry profitability and Medicare/Medicaid reform.

FEDERAL TRADE COMMISSION, Washington, DC 1979-1985 Staff Economist, Antitrust and Regulatory Analysis Divisions, Bureau of Economics Analyzed antitrust and regulatory issues involving computers, hospitals, oil pipelines, electric utilities, securities (stock and futures), soft drinks, and various consumer goods industries.

- 3 - RICHARD P. ROZEK

1982-1983 Deputy Assistant Director for Antitrust, Division of Antitrust, Bureau of Economics Supervised eight staff economists working on various antitrust matters.

UNIVERSITY OF PITTSBURGH, Pittsburgh, PA 1976-1979 Assistant Professor, Department of Economics Taught graduate and undergraduate courses in general equilibrium theory, mathematical economics, mathematics for economists, industrial organization, operations research and microeconomic theory; served on departmental committees; and supervised graduate student research projects.

UNIVERSITY OF IOWA, Iowa City, IA 1973-1976 Research Assistant, Teaching Assistant, Instructor, College of Business Administration

ST. MARY’S COLLEGE, Winona, MN 1972-1973 Instructor, Department of Mathematics Taught undergraduate courses in number theory, integral and differential calculus, probability and statistics.

UNIVERSITY OF MINNESOTA, Minneapolis, MN 1969-1972 Teaching Assistant, School of Mathematics

PUBLICATIONS

“An Economic Perspective on Small and Large Molecule Pharmaceutical Technologies,” forthcoming in Biotechnology Patenting: Three Decades since Diamond v. Chakrabarty (J. Kesan and G. Myles, editors), New York: Oxford University Press, 2013. Spanish version is available on the Cediquifa website.

“Switching Pharmaceutical Products from Prescription to Over-the-Counter: The Debate in the U.S.,” European Journal of Risk Regulation, Volume 3, Issue 4, 2012, pp. 601-607.

“Economics as a Guide to Developing Public Policies for Biosimilar Pharmaceutical Products,” Queen Mary Journal of Intellectual Property, Volume 2, Number 4, 2012, pp. 363-375.

“Risk and Regulatory Factors Affecting Location Decisions by Research-Based Pharmaceutical Companies,” European Journal of Risk Regulation, Volume 2, Issue 1, 2011, pp. 92-103.

"Patent Wars and Authorised Generics in the USA: Assessing the Issues" (with J. Lowe and E. Radel), Healthy IPRs: A Forward Look at Pharmaceutical Intellectual Property (M. Pugatch and A. Jensen, editors), London: The Stockholm Network, 2007.

- 4 - RICHARD P. ROZEK

“Encouraging Cooperation Among the Academic, Government, and Private Sectors in U.S. Biomedical R&D” (with B. Dickensheets), The Intellectual Property Debate: Perspectives from Law, Economics, and Political Economy (M.P. Pugatch, editor), Northampton: Edward Elgar Publishing, Inc., 2006.

“What Is an Idea Worth?” (with G. Korenko), The Intellectual Property Debate: Perspectives from Law, Economics, and Political Economy (M.P. Pugatch, editor), Northampton: Edward Elgar Publishing, Inc., 2006.

“A Market-Based Approach for Tangible Property Transfer Pricing” (with E. Bishko and G. Korenko), Transfer Pricing Report, Volume 13, March 16, 2005, pp. 1110-1115.

“Using In-Country Comparables to Measure the Returns Due Pharmaceutical Marketing and Distribution Affiliates” (with G. Korenko), International Transfer Pricing Journal, Volume 10, November/December 2003, pp. 211-217.

“Investment Incentives Created by the Montreal Protocol and FDA Policy on Albuterol” (with E. Bishko), Journal of World Intellectual Property, Volume 6, November 2003, pp. 807-825.

“Broad-Based Compulsory Licensing of Pharmaceutical Technologies: Unsound Public Policy” (with R. Rainey), Journal of World Intellectual Property, Volume 4, July 2001, pp. 463-480.

“TRIPs Ruling and the Developing Countries: Prospects after Seattle,” Journal of World Intellectual Property, Volume 4, March 2001, pp. 271-275.

“Valuing Intellectual Property Assets for Licensing,” The Law and Business of Licensing: Licensing in the 21st Century (B.I. Friedlander and L.W. Evans, editors), West Group, 2000, pp. 345-362.

“The Effects of Compulsory Licensing on Innovation and Access to Health Care,” Journal of World Intellectual Property, Volume 3, November 2000, pp. 889-917.

“Transfer Prices for the Intangible Property Embodied in Products with Extraordinary Profit Potentials” (with G. Korenko), Tax Notes International, Volume 19, October 18, 1999, pp. 1553-1565.

“The Costs to the U.S. Health Care System of Extending Marketing Exclusivity for Taxol®” (with R. Berkowitz), Journal of Research in Pharmaceutical Economics, Volume 9, September 1999, pp. 21-41.

“The TRIPs Agreement and Access to Health Care” (with N. Tully), Journal of World Intellectual Property, Volume 2, September 1999, pp. 813-819.

- 5 - RICHARD P. ROZEK

“Regulatory Influences on the Decision to Introduce Pharmaceutical Products in Japan” (with T. Nambu and R. Rapp), Journal of World Intellectual Property, Volume 1, September 1998, pp. 763-799.

“The Effects of Patent Protection on the Prices of Pharmaceutical Products” (with R. Berkowitz), Journal of World Intellectual Property, Volume 1, March 1998, pp. 179-243.

“Applying the Best Method Rule When Reliable Internal Comparable Intangibles Exist,” Tax Notes International, Volume 12, April 8, 1996, pp. 1191-1204.

"A Critique of the GAO Report on Differences in Prices for Prescription Drugs between Canada and the United States," Journal of Research in Pharmaceutical Economics, Volume 6, June 1995, pp. 77-91.

"The Health Care System in Canada" (with C. Mulhern), Chapter 4 in Financing Health Care (U.K. Hoffmeyer and T.R. McCarthy, editors), Dordrecht, The Netherlands: Kluwer Academic Publishers, 1994, pp. 255-344.

"The Consequences of Pharmaceutical Product Patenting: A Critique," World Competition, Volume 16, March 1993, pp. 91-106.

"Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation" (with R. Rapp), Journal of Economic Integration, Volume 7, Autumn 1992, pp. 181-203.

"Bidding Theory and the Baseball Player Market," Kentucky Journal of Economics and Business, Volume 11, September 1991, pp. 15-28.

"Discounted Cash Flow Analysis in Patent Infringement Litigation" (with C. Salisbury), Licensing Economics Review, Volume 1, August 1991, pp. 7-10.

"Toward a Definition of Effective Competition in Energy Markets," The Electricity Journal, Volume 4, July 1991, pp. 28-37.

"Benefits and Costs of Intellectual Property Protection in Developing Countries" (with R. Rapp), Journal of World Trade, Volume 24, October 1990, pp. 75-102. Reprinted as "How Property Protection Fuels Economies," les Nouvelles, Volume 27, September 1992, pp. 156-170.

"The Importance of Flexibility in Competitive Resource Procurement" (with L. Nordgulen), The Electricity Journal, Volume 3, June 1990, pp. 48-59.

"Competitive Bidding in Electricity Markets: A Survey," The Energy Journal, Volume 10, October 1989, pp. 117-138.

"Summary of `Price Discrimination and Patent Policy' by J. Hausman and J. MacKie-Mason," Manual on the Economics of Antitrust Law, American Bar Association, Sixth Supplement, Summer 1989, pp. 11.1-11.2

- 6 - RICHARD P. ROZEK

"Technology Transfer: Licensing's Crucial Role," Economic Impact, Number 66, March 1989, pp. 50-54.

"Protection of Intellectual Property Through Licensing: Efficiency Considerations," Journal of World Trade, Volume 22, October 1988, pp. 27-34.

"Differences in Service Mix between For Profit and Nonprofit Hospitals," New York Economic Review, Volume 18, Fall 1988, pp. 43-56.

"Bibliometric Analysis of U.S. Pharmaceutical Industry Research Performance" (with F. Narin), Research Policy, Volume 17, June 1988, pp. 139-154.

"A Nonparametric Test for Economies of Scope," Applied Economics, Volume 20, May 1988, pp. 653-663.

"Intellectual Property and Economic Growth," Economic Impact, Number 62, March 1988, pp. 43-47. Reprinted in Viewpoint, Volume 18, Summer 1989, pp. 23- 29; and Studies in Educational Development (D. Thakur, editor), New Delhi: Deep and Deep Publications, 2004.

"A Bidding Process for a Centralized Market With Trading Out of Equilibrium" (with S. Wu), Journal of Economics/Zeitschrift fur Nationalokonomie, Volume 47, October 1987, pp. 287-307.

"Diversification by Nonprofit Firms: Competitive Implications," Kentucky Journal of Economics and Business, Volume 7, 1986-87, pp. 33-42.

"Protection of Intellectual Property Rights: Research and Development Decisions and Economic Growth," Contemporary Policy Issues, Volume 5, July 1987, pp. 54- 65. Reprinted in Intellectual Property (Patents, Copyrights, Trademarks) Policy and International Negotiations (B.S. Dameron, editor), Washington: International Law Institute, 1987; and Intellectual Property Rights in Science, Technology, and Economic Performance: International Comparisons (F.W. Rushing and C.G. Brown, editors), Boulder: Westview Press, 1990.

"On the Behavior of For Profit and Nonprofit Hospitals," Proceedings of the Inaugural Meeting of the Pennsylvania Economic Association, Volume 1, May 1986, pp. 200-212.

"Competition as a Complement to Regulation," The Energy Journal, Volume 6, July 1985, pp. 79-90.

"The Over-Capitalization Effect with Diversification and Cross Subsidization," Economics Letters, Volume 16, October 1984, pp. 159-163.

"The Role of Market Power Measures in the Search for an Antitrust Case," The American Economist, Volume 28, Fall 1984, pp. 36-40.

- 7 - RICHARD P. ROZEK

“The Inflation-Induced Discrepancy between Accounting and Economic Rates of Return” (Abstract), Financial Review, Volume 19, June 1984, p. 118.

"Rate of Return Regulation and Vertical Integration Under Uncertainty," Mathematical Modelling, Volume 4, July 1983, pp. 87-96.

"Brand Identification and Advertising: The Case of a Generic Trademark," Applied Economics, Volume 14, June 1982, pp. 235-248.

"A Model of the Firm's Demand for Money under Uncertainty" (with S. Wu), Metroeconomica, Volume 31, June 1979, pp. 225-241.

"The Effects of Imperfect Information on Market Equilibrium," Papers and Proceedings: Southwestern Society of Economists, Volume 4, March 1979, pp. 235- 240.

"The Formation of a Trader's Reservation Price," Atlantic Economic Journal, Volume 6, July 1978, p. 92.

"Numerical Examples of a Market Adjustment Mechanism" (with G. Moulton), Modeling and Simulation, Volume 8, December 1977, pp. 1027-1031.

THESES

"A Non-Tatonnement Bidding Process for a Centralized Market," unpublished Ph.D. thesis, University of Iowa, 1976.

"Topologies on Function Spaces," unpublished M.A. thesis, University of Minnesota, 1971.

HONORS AND PROFESSIONAL ACTIVITIES

Referee for Antitrust Bulletin, Applied Economics, Contemporary Policy Issues, The Energy Journal, Journal of Research in Pharmaceutical Economics, Jurimetrics: The Journal of Law, Science, & Technology, Managerial and Decision Economics, and Social Science Quarterly.

Listed, Guide to the World's Leading Transfer Pricing Advisers, Legal Media Group, 2011

Invited Participant, U.S. Information Agency, American Participant Program in Argentina and Brazil, 1990.

Invited Discussant, Illinois Institute of Technology, Center for the Study of Ethics in the Professions, Conference on Intellectual Property, 1985.

- 8 - RICHARD P. ROZEK

Invited Participant, Institute of Health Economics and Social Studies, Seminar on the Pharmaceutical Industry, 1978.

Awarded Summer Research Grant, University of Pittsburgh, Faculty of Arts and Sciences, 1978.

Invited Participant, Chicago Board of Trade, Summer Intern Program, 1977.

Received Commendation for Excellence in Teaching, University of Iowa, 1976.

Awarded Teaching and Research Assistantships, University of Minnesota and University of Iowa, 1969-1972 and 1973-1976, respectively.

Awarded HEW Scholarship, College of St. Thomas, 1965-1969.

Member: American Economic Association, Beta Gamma Sigma (National Honor Society in Business and Management), Delta Epsilon Sigma (National Scholastic Honor Society), and Omicron Delta Epsilon (International Honor Society in Economics).

SPEECHES

“Debt /Equity Considerations and Related Transfer Pricing Implications,” speech at the National Association for Business Economics Transfer Pricing Symposium, 2012.

“An Economic Perspective on Small and Large Molecule Pharmaceutical Technologies,” speech at the University of Illinois symposium on Patenting in the Biotechnology Industry: 30 Years after Diamond v. Chakrabarty, 2010.

“Patents in a Global Economy: Identifying the Benefits,” speech at the Fédération Internationale des Conseils en Propriété Industrielle World Congress, 2009.

“The Role of Economic Analysis in Guiding Public Policy,” seminar presentation at the University of Maryland, 2008.

“Transforming Ideas: Laboratory to Patient” and “Key Factors in Attracting Internationally Mobile Investments by the Research-Based Pharmaceutical Industry,” seminar presentations at Duquesne University, 2008.

“Antitrust Laws, Life Cycle Management, and the Incentives to Invest in Pharmaceutical R&D,” speech at Federal Trade Commission/Department of Justice Hearings on Single-Firm Conduct, 2006.

“Economic Trends: Prospects for Venture Capital Investment in Biotechnology,” speech at the Mid-Atlantic BIO/MED Conference and Exhibition—Venture and Investment Forum, 2003.

- 9 - RICHARD P. ROZEK

“Innovation, Competition, and Choice in the U.S. Healthcare System,” speech at the International Symposium on Healthcare Policies and Reference Pricing (Seoul), 2001.

“Avoiding Public Policy Failures: The Role of Compulsory Licensing,” speech at the conference on TRIPs, Development, and Public Health (Geneva), 2001.

“TRIPs Rulings and Developing Countries: Prospects after Seattle,” speech at the Geneva Global Arbitration Forum, 2000.

“The Gray Market: Economic Aspects of Exhaustion in Europe and the U.S.,” speech at the American Intellectual Property Law Association Annual Meeting, 2000.

“Opportunities for Commercial Success of an Innovation from Emerging Patent Regimes,” speech before the Inventors’ Network of the Capital Area, 2000.

“How to Energize the Intellectual Property Debate,” speech at the roundtable Challenges and Opportunities in Intellectual Property Protection for Pharmaceutical Products (Barcelona), 1999. The proceedings of the conference published as “Intellectual Property Protection for Pharmaceuticals: Emerging Issues in the Global Economy,” The Pfizer Journal – Global Edition, Volume 1, No. 2, 2000.

“Valuing Intellectual Property Assets for Licensing,” speech at the Insight Information Conference on Negotiating and Drafting Licensing Agreements, 1999.

“Applying the Best Method Rule When Reliable Internal Comparable Intangibles Exist,” speeches at the Global Educational Services Seminar on Tax Aspects of Intercompany Pricing, 1998; and the Committee to Study Multinational Trade Issues, 1999.

“The Effects of Patent Protection on the Prices of Pharmaceutical Products,” speeches at the Southern Economic Association Annual Meeting, 1997; the IMS Global Services Annual Client Meeting, 1998; and Ciencia y Crecimiento (Buenos Aires), 1999.

“Impact of the Telecommunications Act of 1996 on Employment and Training,” speech at the Joint Employment & Training Technology Conference, 1996.

“Vertical Integration in the Pharmaceutical Industry,” speech at the NERA Seventeenth Annual Antitrust & Trade Regulation Seminar, 1996.

"Efficiency and Health Care Reform," speech at the Reunion International De Expertos En Seguridad Social (Mexico City), 1995.

"Meeting the Future Challenges of Health Care Reform," speech at the Institute for International Research Conference on Patient Information, Education and Compliance Programs, 1993.

- 10 - RICHARD P. ROZEK

"Setting The Economic Scene for the Next Seven Years: Health Care," speech at the Annual Meeting of the Actuarial Society of Greater New York, 1993.

"Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation," speech at the Southern Economic Association Annual Meeting, 1992.

"The Use of Bidding and Auctioning Models in Competition Analyses," speech at the NERA Twelfth Annual Antitrust & Trade Regulation Seminar, 1991.

"Benefits and Costs of Intellectual Property Protection in Developing Countries," a series of speeches before academic, business and government groups in Argentina and Brazil, 1990; lecture to graduate students in the International Management Program at the University of Maryland, 1990; and presentation at a seminar sponsored by the Minister of Health in Turkey, 1992.

"Competitive Procurement of Generating Capacity: The Importance of Flexibility," speech at the Pacific Northwest Supply and Demand-Side Competitive Bidding Workshop, 1990; presentation at a Federal Energy Regulatory Commission Staff Seminar, 1990.

"Merger Analysis and Policy: Three Examples of Geographic Market Definition Under the DOJ Guidelines," speech at the NERA Tenth Annual Antitrust & Trade Regulation Seminar, 1989.

"Competitive Bidding in Energy Markets: A Policy Analysis," speech at the Eastern Economic Association Annual Meeting, 1989.

"Bibliometric Analysis of U.S. Pharmaceutical Industry Research Performance," speech at the Southern Economic Association Annual Meeting, 1987.

"Diversification by Nonprofit Firms: Competitive Implications," seminar presentations at the University of Hartford, University of Southern California and University of Iowa, 1987.

"Public Policy Issues Affecting the U.S. Pharmaceutical Industry," seminar presentation at Villanova University, 1987.

"Measuring the Returns to the R&D Investment," seminar presentation at the National Institutes of Health STEP Seminar, 1987.

"Protection of Intellectual Property Through Licensing: Efficiency Considerations," speech at the Eastern Economic Association Annual Meeting, 1987.

"The Protection of Intellectual Property Rights: R&D Decisions and Economic Growth," speech at the Western Economic Association Annual Meeting, 1986; and a revised version presented at the National Science Foundation--U.S. Chamber of Commerce Symposium on Protection of Intellectual Property Rights in Science, Technology, and Economic Performance: International Comparisons, 1989.

- 11 - RICHARD P. ROZEK

"Service Mix and Economies of Scope in the Hospital Industry," speech at the Eastern Economic Association Annual Meeting, 1986.

"On the Behavior of For Profit and Nonprofit Hospitals," speech at the Pennsylvania Economic Association Annual Meeting, 1986.

"The Cost Effectiveness of Drugs," speech at the Southeastern Pharmacy Education Conference, 1985.

"Competition as a Complement to Regulation," speech at the Eastern Economic Association Annual Meeting, 1985.

"The Role of Market Power Measures in the Search for an Antitrust Case," speech at the Midwest Economics Association Annual Meeting, 1984.

"Rate of Return Regulation and Vertical Integration under Uncertainty," speech at the Southern Economic Association Annual Meeting, 1983.

"Advertising and Generic Trademarks," speech at the Eastern Economic Association Annual Meeting, 1980.

"Mathematics for Economists: A Two Course Sequence," speech at the Annual Meeting of the Mathematical Association of America--Maryland, District of Columbia, Virginia Section, 1979.

"The Effects of Imperfect Information on Market Equilibrium: A Survey," speech at the Southwestern Society of Economists Annual Meeting, 1979.

"The Formation of a Trader's Reservation Price," speech at the Annual Pittsburgh Modeling and Simulation Conference, 1978.

"The Effects of Uncertainty on the Firm's Demand for Money," speech at the Southwestern Economics Association Annual Meeting, 1978.

"Numerical Examples of a Market Adjustment Mechanism," speech at the Annual Pittsburgh Modeling and Simulation Conference, 1977.

"A Bidding Process for a Centralized Atomistic Market with Trading Out of Equilibrium," seminar presentations at the University of Missouri and University of Pittsburgh, 1976, and the Federal Trade Commission, 1978; speech at the Southern Economic Association Annual Meeting, 1978; and a revised version presented at a Federal Energy Regulatory Commission Staff Seminar, 1987.

"Uncertainty, Transactions Motive, and the Demand for Money," speech at the Econometric Society Meeting, 1974.

- 12 - RICHARD P. ROZEK

DEPOSITIONS AND TESTIMONY

Declaration on behalf of Stiefel Laboratories, Inc. in the matter of Medicis Pharmaceutical Corporation and Alyzan, Inc. vs. Stiefel Laboratories, Inc., U. S. District Court for the Western District of Texas, San Antonio Division, Civil Action No. SA-10-cv-0621-OG, October 12, 2010.

Expert Report and Deposition on behalf of Sanofi-Aventis in the matter of Aventis Pharmaceuticals Inc., Merrell Pharmaceuticals Inc., and Carderm Capital L.P. vs. Impax Laboratories, Inc., et al., U.S. District Court for the District of New Jersey, Civil Action Nos. 02-1322 (JAG consolidated) and Coordinated Actions: No. 02- 1322(JAG), No. 03-1179(JAG), No. 03-1180(JAG), No. 03-5108(JAG), No. 03- 5829(JAG), No. 04-222(JAG), No. 04-1075(JAG), No. 04-1076(JAG), No. 04- 1077(JAG), No. 04-1078(JAG), No. 04-1731(JAG), No. 04-2305(JAG), No. 04- 3194(JAG), No. 04-3944(JAG), No. 05-4255(JAG), No. 06-1277(JAG), No. 06- 5463(JAG), No. 07-2454(JAG), No. 07-5054(JAG), No. 07-5180 (JAG), No. 08- 254(JAG), No. 09-325(JAG), May 27, 2009 and September 21, 2010, respectively.

Expert Report, Deposition, and Testimony on behalf of Sanofi-Aventis in the matter of Alfuzosin Hydrochloride Patent Litigation, U.S. District Court for the District of Delaware, MDL Docket No. 08-md-1941 (GMS), December 1, 2009, January 15, and May 5, 2010, respectively.

Testimony on behalf of the Acetochlor Registration Partnership in the matter of Acetochlor Registration Partnership and its Partners (Dow ArgoSciences LLC and Monsanto Company) vs. Agan Chemical Manufacturers, Ltd. and Drexel Chemical Company, American Arbitration Association, Case Number 16 171 Y 00210 08, September 18 and 24, 2009.

Declaration, Deposition, and Testimony on behalf of Kimberly-Clark Corporation in the matter of Kimberly-Clark Worldwide, Inc. and Kimberly-Clark Global Sales, LLC vs. Tyco Healthcare Group, L.P. (d/b/a Covidien), Mallinckrodt, Inc., and Nellcor Puritan Bennett, LLC, U.S. District Court for the Eastern District of Wisconsin, Green Bay Division, Civil Action No. 09-C-429, June 18, 23, and 25, 2009, respectively.

Declaration, Declaration (Commercial Success), and Declaration (IMS Data) on behalf of Ortho-McNeil Pharmaceutical, Inc. in the matter of Ortho-McNeil Pharmaceutical, Inc. vs. Apotex, Inc., U.S. District Court for the Northern District of Illinois, Eastern Division, Civil Action No. 07-cv-4050, June 19, July 17, and July 17, 2008, respectively.

Declaration and Supplemental Declaration on behalf of Alza Corporation in the matter of In re Patent Application of: ALZA CORPORATION, U.S. Patent and Trademark Office, Reexamination Application No: 90/008,142, March 19, 2007 and April 10, 2008, respectively.

- 13 - RICHARD P. ROZEK

Expert Report, Deposition, Testimony, Declaration (Injunctive Relief), and Declaration (Interest and Post-Trial Damages) on behalf of LifeNet Health Inc. in the matter of LifeNet, Inc. vs. Musculoskeletal Transplant Foundation, Inc., U.S. District Court for the Eastern District of Virginia, Richmond Division, Civil Action No. 3:06-cv-00387 (HEH), July 9, July 31, October 17, 2007, April 7, and April 8, 2008, respectively.

Declaration and Deposition on behalf of Ortho-McNeil Pharmaceutical, Inc. in the matter of Ortho-McNeil Pharmaceutical, Inc. vs. Kali Laboratories, Inc., Par Pharmaceutical Companies, Inc., Par Pharmaceutical, Inc., Barr Laboratories, Inc., and Caraco Pharmaceutical Laboratories, Ltd., U.S. District Court for the District of New Jersey, Civil Action No.: 06-cv-3533 (JCL) (MF) (Consolidated with Civil Action No.: 04-0866), January 22 and February 6, 2008, respectively.

Expert Report, Deposition, and Testimony on behalf of Alza Corporation and McNeil-PPC, Inc. in the matter of Alza Corporation and McNeil PPC, Inc. vs. Andrx Pharmaceuticals, LLC and Andrx Corporation, U.S. District Court for the District of Delaware, Civil Action No. 05-642-JJF, July 11, July 19, and December 14, 2007, respectively.

Expert Report and Deposition on behalf of Schiller America, Inc. and Schiller AG in the matter of Schiller America, Inc. and Schiller, A.G. vs. Welch Allyn, Inc., U.S. District Court for the Southern District of Florida, Miami Division, Case No.: 06- 21439-CIV-Lenard/Torres, September 11 and September 28, 2007, respectively.

Expert Report, Supplemental Expert Report, Deposition, and Second Supplemental Expert Report on behalf of SmithKline Beecham plc in the matters of SmithKline Beecham plc, et al, vs. Teva Pharmaceuticals USA, Inc., U.S. District Court for the District of New Jersey, Civil Action Nos. 03-4037 (NLH), 04-215 (NLH), and 05-536 (NLH); and SmithKline Beecham plc, et al. vs. Dr. Reddy's Laboratories, Ltd., U.S. District Court for the District of New Jersey, Civil Action No. 03-4179 (NLH), October 16, 2006, January 22, February 8, and May 31, 2007, respectively.

Declaration and Reply Declaration on behalf of Aventis Pharmaceuticals Inc. in the matters of Aventis Pharmaceuticals Inc. et al. vs. Barr Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; Barr Laboratories, Inc. and Ranbaxy Laboratories Limited and Ranbaxy Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc. and Amino Chemicals Ltd.; U.S. District Court for the District of New Jersey, Civil Action Nos. 01-3627 (JAG consolidated); 03-487 (JAG); 04-1064 (JAG); and 04- 1078, September 16 and October 20, 2005.

- 14 - RICHARD P. ROZEK

Expert Report and Deposition on behalf of Ortho-McNeil Pharmaceutical, Inc. in the matter of Ortho-McNeil Pharmaceutical, Inc. vs. Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc., U.S. District Court for the District of New Jersey, Civil Action No. 3:04-1689 (SRC), June 14 and July 22, 2005, respectively.

Expert Report, Rebuttal Expert Report, and Deposition on behalf of Ortho-McNeil Pharmaceutical, Inc. in the matter of Ortho-McNeil Pharmaceutical, Inc. vs. Kali Laboratories, Inc., U.S. District Court for the District of New Jersey, Civil Action No. 02-5707-JCL, July 19, November 19, and December 14, 2004, respectively.

Deposition on behalf of Apotex Corporation in the matter of Apotex Corporation and Torpharm Inc. vs. Pharmaceutical Formulations, Inc., Circuit Court of Cook County, Illinois County Department, Law Division, Case No. 00 CH 10838, June 17, 2004.

Declaration and Reply Declaration on behalf of Janssen Pharmaceutica N.V. in the matter of Janssen Pharmaceutica N.V., et al. vs. Eon Labs Manufacturing, Inc., U.S. District Court for the Eastern District of New York, Civil Action No. 01-CV- 2322 (NG) (MDG), March 15 and April 29, 2004, respectively.

Expert Report, Deposition, and Testimony on behalf of Teva Pharmaceuticals USA, Inc. in the matter of Merck & Co., Inc. vs. Teva Pharmaceuticals USA, Inc., U.S. District Court for the District of Delaware, Civil Action No. 01-048-JJF (Consolidated), January 10, February 4, and March 7, 2003, respectively.

Expert Report, Supplemental Expert Report, and Deposition on behalf of Robert M. Worcester, MORI/USA Corporation, and Market & Opinion Research International, Ltd. in the matter of Miguel Basanez and MORI de Mexico SA de CV vs. Robert M. Worcester, MORI/USA Corporation, and Market & Opinion Research International, Ltd., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. MER-C-66-00, May 28, June 24, and June 27, 2002, respectively.

Expert Report, Deposition, and Declaration on behalf of Rhone-Poulenc Rorer in the matter of Watson Laboratories, Inc. vs. Rhone-Poulenc Rorer, Inc., Rhone- Poulenc Rorer Pharmaceuticals, Inc., Rorer Pharmaceutical Products, Inc., U.S. District Court for the Central District of California, Western Division, Case No. 99- 07947 Ahm (Rzx), October 5, 2000; May 3-4 and July 17, 2001; and September 6, 2001, respectively.

Expert Report and Deposition on behalf of Blue Cross and Blue Shield of Michigan in the matters of Blue Cross and Blue Shield of Michigan vs. PCS Health Systems, Inc., U.S. District Court for the District of Arizona, Case Nos. CIV 98-1620-PHX- PGR and CIV 99-444-PHX-EHC (Consolidated), February 15, 2000 and March 16, 2001, respectively.

- 15 - RICHARD P. ROZEK

Expert Report and Deposition on behalf of Abbott Laboratories, Geneva Pharmaceuticals, Inc., and Zenith Goldline Pharmaceuticals, Inc. in the matter of In Re Terazosin Hydrochloride Antitrust Litigation, U.S. District Court for the Southern District of Florida, Southern Division, Case No. 99-MDL-1317- Seitz/Garber, August 18 and September 12, 2000, respectively.

Deposition and Testimony on behalf of Unimed Pharmaceuticals, Inc. in the matter of Roxane Laboratories, Inc. vs. Unimed Pharmaceuticals, Inc., U.S. District Court for the Southern District of Ohio, Eastern Division, Case No. C2 00 125, August 24 and September 7, 2000, respectively.

Expert Reports and Deposition on behalf of Novartis Pharmaceuticals Corporation in the matter of Zenith Goldline Pharmaceuticals, Inc. vs. Novartis Pharmaceuticals Corporation, U.S. District Court for the District of New Jersey, Civil Action No. 98-4244(JWB), November 29, 1999 and March 17, 2000 (Reports); and February 4, May 18-19, 2000 (Deposition).

Expert Reports and Deposition on behalf of Abbott Laboratories in the matter of Microbix Biosystems, Inc. vs. BioWhittaker, Inc., BioWhittaker Holdings, Inc., and Abbott Laboratories, U.S. District Court for the District of Maryland, Case No. MJG 97-2525, November 15 and December 17, 1999 (Reports), and December 2, 1999 (Deposition).

Declaration on behalf of PMR Corporation and Stadt Solutions, LLC in the matter of PMR Corporation and Stadt Solutions, LLC vs. Bergen Brunswig Corporation, PharMerica, Inc., Stadtlander Operating Company, LLC and DOES 1 through 50, Superior Court of the State of California for the County of San Diego, Case No. 729889, April 15, 1999.

Expert Reports, Deposition, and Testimony on behalf of Ferndale Laboratories, Inc. in the matter of Ferndale Laboratories, Inc. vs. Block Drug Company, Inc., Reed & Carnrick Division, and Schwarz Pharma, Inc., U.S. District Court for the Eastern District of Michigan Southern Division, Case No. 95-CV-12796-DT, June 12, October 31, 1997, January 15, February 1, 1999 (Reports); July 30, August 5, November 10, 1997, and February 4, 1999 (Deposition); and February 26, March 2-3, 1999 (Testimony).

Expert Report, Deposition, and Testimony on behalf of Solvay Pharmaceuticals, Inc. in the matter of Pharmacia & Upjohn Company vs. Solvay Pharmaceuticals, Inc., American Arbitration Association, Atlanta Tribunal, Case No. 30 Y 199 00185 98, November 9, 1998, January 8, 1999, and January 27, 1999, respectively.

- 16 - RICHARD P. ROZEK

Expert Reports, Deposition, and Testimony on behalf of Roche Holding Ltd. and Hoffmann-LaRoche, Inc. in the matter of KV Pharmaceutical Company and ETHEX Corporation vs. Roche Holding Ltd. and Hoffmann-LaRoche, Inc., American Arbitration Association, Case No. 13-T-181-00410-97, October 23, 1997, April 20, June 12, and June 19, 1998 (Reports); October 29, 1997, May 1, September 10 and September 29, 1998 (Deposition); and October 1-2, 1998 (Testimony).

Testimony (written) on behalf of Peninsula Regional Medical Center In Re: The Full Rate Application of Peninsula Regional Medical Center, Inc., Salisbury, Maryland, before the Health Services Cost Review Commission, Docket 1998, Folio 1177, Proceeding 1367R, June 29, 1998.

Expert Reports and Deposition on behalf of Zeneca Ltd. in the matters of Zeneca Ltd. vs. Mylan Pharmaceuticals, Inc., U.S. District Court for the Western District of Pennsylvania, Civil Action No. 96-333; and Zeneca Ltd. vs. Pharmachemie B.V., U.S. District Court for the District of Massachusetts, Civil Action No. 96-12413- RCL, March 6, 1998 (Reports); April 29 and May 15, 1998 (Deposition).

Testimony on behalf of Immunomedics, Inc. in the matter of Immunomedics, Inc. vs. Pharmacia & Upjohn, Inc., American Arbitration Association, Case No. 13-199- 00452-96, April 2, 1997.

Declaration on behalf of Hoechst Marion Roussel, Inc. in the matter of Mutual Pharmaceutical Company, Inc. vs. Hoechst Marion Roussel, Inc., U.S. District Court for the Eastern District of Pennsylvania, Civil Action No. 96-1409, filed November 27, 1996.

Deposition and Testimony on behalf of Behring Diagnostics Inc. in the matter of Cambridge Biotech Corporation, Debtor, U.S. Bankruptcy Court for the District of Massachusetts, Case No. 94-43054-JFQ, June 21 and June 24, 1996, respectively.

Expert Report and Deposition on behalf of Wakefern Food Corp. in the matter of Private Label Brokers Group vs. Wakefern Food Corp. and Marketing Management Inc., Superior Court of New Jersey, Chancery Division, Union County, Docket No. UNN-C-34-95, May 1 and May 15, 1996, respectively.

Testimony on behalf of Pfizer Inc. in the matter of Pfizer Inc. vs. PCS Health Systems, Inc., Clinical Pharmaceuticals, Inc. D/B/A Clinical Pharmacy Advantage and CPA Health Systems, Inc., Supreme Court of the State of New York, County of New York: Trial Term Part 27, Index No. 126154/95, March 20-21, 1996.

Declaration and Deposition on behalf of NERA In Re Brand Name Prescription Drug Antitrust Litigation, U.S. District Court for the Northern District of Illinois Eastern Division, Master File No. 94 C 897, July 20 and October 3, 1995, respectively.

- 17 - RICHARD P. ROZEK

Affidavit in the matter of U.S. vs. Western Electric Co. and American Telephone and Telegraph Company, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting the “Motion of BellSouth Corporation for a Waiver of Sections II(A) and II(D) of the Modification of Final Judgment to Allow BellSouth to Provide Integrated MultiLATA Personal Communications Service,” filed December 27, 1995.

Affidavit on behalf of BellSouth Corporation before the Federal Communications Commission in the matter of Equal Access and Interconnection Obligations Pertaining to Commercial Mobile Radio Services, CC Docket No. 94-54, RM-8012, filed October 13, 1994.

Affidavits on behalf of BellSouth Corporation before the Federal Communications Commission in the matters of the Petition of Public Utilities Commission, State of Hawaii, for Authority to Extend Its Rate Regulation of Commercial Mobile Radio Services in the State of Hawaii and Petition on Behalf of the Louisiana Public Service Commission for Authority to Retain Existing Jurisdiction Over Commercial Mobile Radio Services Offered Within the State of Louisiana, PR File Nos. 94-SP1 and 94-SP5, filed September 19, 1994.

Affidavit (with H. Ware) in the matter of U.S. vs. Western Electric Co. and American Telephone and Telegraph Company, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting the "Reply of BellSouth Corporation in Support of its Motion for Generic Wireless Relief," filed September 2, 1994.

Affidavit on behalf of BellSouth Corporation before the Federal Communications Commission in the matter of Amendment of the Commission's Rules to Establish New Personal Communications Services, GEN Docket No. 90-314, filed August 30, 1994.

Affidavit (with H. Ware) in the matter of U.S. vs. Western Electric Co. and American Telephone and Telegraph Company, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting "BellSouth Corporation's Opposition to AT&T's Motion for a Waiver of Section I(D) of the Decree Insofar as it Bars the Proposed AT&T-McCaw Merger," filed June 28, 1994.

Affidavit, Reply Affidavit and Affidavit (with H. Ware) on behalf of BellSouth Corporation before the Federal Communications Commission in the matter of AT&T-McCaw Merger, In re Applications of American Telephone and Telegraph Company and Craig O. McCaw For Consent to the Transfer of Control of McCaw Cellular Communications, Inc. and its Subsidiaries, File No. ENF-93-44, filed November 1, 1993, January 18, 1994 and June 20, 1994, respectively.

- 18 - RICHARD P. ROZEK

Deposition and Testimony on behalf of Alpha 1 Biomedicals, Inc. in the matter of Alpha 1 Biomedicals, Inc. vs. SciClone Pharmaceuticals, Inc., American Arbitration Association, Case No. 74 E 113 00902 93, January 13 and February 11-12, 1994, respectively.

Declaration on behalf of Alpha 1 Biomedicals, Inc. in the matter of SciClone Pharmaceuticals, Inc. vs. Alpha 1 Biomedicals, Inc., U.S. District Court for the Northern District of California, Civil Action No. C93-3464-CAL, October 1, 1993.

Affidavit, Deposition, and Testimony on behalf of American Cyanamid Company in the matter of Mylan Pharmaceuticals, Inc. vs. American Cyanamid Company vs. Roy McKnight, U.S. District Court for the Northern District of West Virginia, Civil Action No. 90-0121-C(S), January 20, August 6-7, and September 21-23, 1993, respectively.

Deposition and Testimony on behalf of Dornier Medical Systems, Inc. in the matter of Technical Resource Services, Inc. vs. Dornier Medical Systems, Inc., U.S. District Court for the Middle District of Florida - Orlando Division, Civil Action No. 91-762-CIV-ORL-19, January 26 and June 22-23, 1993, respectively.

Declaration and Reply Declaration on behalf of Xoma Corporation in the matter of Xoma Corporation vs. Centocor, Inc., U.S. District Court for the Northern District of California, Civil Action No. C-90-1129-RHS, January 8 and March 7, 1992, respectively.

Deposition on behalf of Xoma Corporation in the matter of Xoma Corporation vs. Centocor, Inc., U.S. District Court for the Northern District of California, Civil Action No. C-90-1129-RHS; and "Certain Monoclonal Antibodies Used for Therapeutically Treating Humans Having Gram Negative Bacterial Infections," U.S. International Trade Commission, Investigation No. 337-TA-323, June 27, 1991.

Affidavit (with C. Jackson) in the matter of U.S. vs. Western Electric Co. and American Telephone and Telegraph Company, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting the "Request by BellSouth Corporation for a Waiver of the Modification of Final Judgment to Allow BellSouth Corporation to Provide Integrated MultiLATA Cellular Service," filed May 9, 1991.

Testimony (written) on behalf of Eighteen Vermont Utilities before the Federal Energy Regulatory Commission in the matter of Northeast Utilities Service Company (Re: Public Service Company of New Hampshire), Docket Nos. EC90- 10-000, ER90-143-000, ER90-144-000, ER90-145-000 and EL90-9-000, May 25, 1990.

Deposition on behalf of Ortho Pharmaceutical Corp. in the matter of Ortho Pharmaceutical Corp. vs. Amgen, Inc., Endispute Arbitration, August 22 and September 15, 1989.

- 19 - RICHARD P. ROZEK

Deposition on behalf of McGraw Edison Company in the matter of Augustus Oliviere vs. McGraw Edison Company, et al, U.S. District Court for the District of Columbia, Civil Action No. 87-600-JHP, November 11, 1987.

OTHER REPORTS PREPARED IN LITIGATION

“Expert Report on Damages,” prepared for Expert Choice, Inc. vs. Gartner, Inc. vs. Ernest Forman, U.S. District Court for the District of Connecticut, Civil Action No. 3:03cv02234(CFD), April 2006.

“Expert Report on Damages,” prepared for Classified Cosmetics, Inc. vs. Del Laboratories, Inc., U.S. District Court for the Central District of California-Western Division, Civil Action No. CV-03-4818 AHM (PLAx), March 2005.

“Damages to Roche from Wyeth-Ayerst’s Failure to Supply Tubex®” and “Reply to Wyeth-Ayerst’s Comments on Roche’s Damage Claims,” prepared for In Re Private Commercial Mediation: Hoffmann-La Roche Inc. and Wyeth-Ayerst, July 2001 and September 2001, respectively.

“Expert Report on Damages,” prepared for Purepac Pharmaceutical Co. vs. Hoechst Celanese Corporation, Supreme Court of the State of New York, County of New York, Index No. 605575/97, June 2000.

“Expert Report on Damages,” prepared for Avery Dennison Corporation vs. UCB Films PLC, U.S. District Court for the District of Illinois, Eastern Division, Civil Action No. 95 C 6351, March 2000.

“Expert Report on Damages,” prepared for Leslie Atkins, d/b/a Leslie Atkins Communications, vs. Benson J. Fischer, The Fischer Organization, Inc., and the Fischer Brewing Company, Inc., U.S. District Court for the District of Columbia, Civil Action No. 98CV00800, September 1999.

“Expert Report on Damages,” prepared for Schering Corporation and Biogen, Inc. vs. Amgen, Inc., U.S. District Court for the District of Delaware, Civil Action No. 96-587-MMS, September 1998.

“Critique of the Report Submitted on Behalf of the University of Georgia Research Foundation Concerning Damages,” prepared for The University of Georgia Research Foundation vs. Kilpatrick & Cody, State Court of Fulton County, State of Georgia, December 1996.

- 20 - RICHARD P. ROZEK

"Report on Damages to Ortho Pharmaceutical Corporation Due to the Injunction Prohibiting Sales of its Norgestimate Products," (with R. Rapp and C. Salisbury), prepared for American Home Products Corporation and Herchel Smith vs. Johnson & Johnson Corporation and Ortho Pharmaceutical Corporation, U.S. District Court for the Eastern District of Pennsylvania, Civil Action No. 91-5594, November 1993.

"Legal and Economic Theories of Contracts and Contract Discharge," prepared as background in Wendy's International, Inc. vs. Pepsico, Inc., U.S. District Court for the Southern District of Ohio, Civil Action No. C2-86-1403, December 1987.

"Analysis of Market Power Using SAC," prepared as background in ETSI Pipeline Project vs. Burlington Northern, Inc. et al, U.S. District Court for the Eastern District of Texas, Civil Action No. B-84-979, October 1987.

PUBLIC POLICY STUDIES

“Key Factors in Attracting Internationally Mobile Investments by the Research- Based Pharmaceutical Industry,” (with E. Bramley-Harker, D. Lewis, and J. Farahnik), prepared for U.K. Trade & Investment and the Association of the British Pharmaceutical Industry, September 2007.

“Complementary Roles of Government, Academia, and Industry in the Biomedical R&D Process,” (with B. Geiman), prepared for the Pharmaceutical Research and Manufacturers of America, November 2001.

“Patients are Waiting for Treatments and Cures: Ten Diseases,” prepared for the Pharmaceutical Research and Manufacturers of America, August 2001. “Profile of the Generic Pharmaceutical Industry in the United States,” prepared for the Pharmaceutical Research and Manufacturers of America, July 2001.

“The Effects of Compulsory Licensing on Innovation and Access to Health Care,” (with R. Rainey), prepared for the International Federation of Pharmaceutical Manufacturers Associations, September 2000.

“The Costs to Patients Associated with Switching Pharmaceutical Products from Prescription to Over-the-Counter: A Survey,” (with A. Carey), prepared for a research-based pharmaceutical firm, May 2000.

“The Effects of Patent Protection on the Prices of Pharmaceutical Products,” (with R. Berkowitz), prepared for the Pharmaceutical Research and Manufacturers of America, January 1998.

“The Costs to the U.S. Health Care System of Extending Marketing Exclusivity for Taxolâ,” prepared for Immunex Corporation, March 1997.

- 21 - RICHARD P. ROZEK

"Profile of the Health Care System in Canada" and "Reform of the Health Care System in Canada," (with C. Salisbury), prepared as part of the volume The Health Care System in Canada for the project Financing Health Care with Particular Reference to Medicines, April 1993.

"The Consequences of Pharmaceutical Product Patenting: A Critique," prepared for the Pharmaceutical Manufacturers Association, December 1992.

"Review of the GAO Report: Prescription Drugs: Companies Typically Charge More in the United States Than in Canada," prepared for a research-based pharmaceutical firm, November 1992.

"Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation," (with R. Rapp), prepared for the Pharmaceutical Manufacturers Association, July 1992 (NERA Working Paper No. 16).

"Economics of the Research-Based Pharmaceutical Industry," (with C. Salisbury), prepared for the Pharmaceutical Manufacturers Association, February 1992.

"Benefits and Costs of Intellectual Property Protection in Developing Countries," (with R. Rapp), prepared for a group of pharmaceutical firms interested in including intellectual property rights in the GATT, June 1990 (NERA Working Paper No. 3).

"Update on Utility Competitive Bidding Programs," (with L. Nordgulen), prepared for the Energy Research Group, February 1989.

"A Guide to the Economics of Bidding and Auctioning Processes," prepared for the Energy Research Group, November 1987.

REPORTS PREPARED FOR ANTITRUST OR REGULATORY REVIEWS

“Economic Issues Raised in the FDA’s Proposed Rule on Removing the Essential- Use Designation for Albuterol MDIs” and “Factors that Improve Patient Access after Removing the Essential-Use Designation for Albuterol CFC MDIs,” (with E. Bishko), prepared in response to Federal Register Notice, dated June 16, 2004, regarding FDA Docket No. 2003P-0029, August 13, 2004 and February 18, 2005, respectively.

“The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an Ozone Depleting Substance,” (with E. Bishko), prepared in response to Citizen Petition of the U.S. Stockholders Group on MDI Transition (FDA Docket No. 03P-0029), September 8, 2003. Results presented at the FDA Pulmonary- Allergy Drugs Advisory Committee Meeting, June 10, 2004.

- 22 - RICHARD P. ROZEK

"Analysis of Employee Zip Code Data for Determining Geographic Labor Markets," (with G. Korenko and E. Bishko), prepared for The Association of Maryland Hospitals & Health Systems, November 26, 2002.

"Answers to the DOJ Questions on the Competitive Effects of the PMA Undertaking," prepared for the Pharmaceutical Manufacturers Association, April 1993.

"The Commission Should Close Its Investigation of Lamar's Acquisition of Metro," (with J. McDavid and C. Lamar), prepared for a client involved in a FTC investigation, May 1992.

"An Analysis of a Proposed Acquisition by R.P. Scherer International Corporation," prepared to help a client assess the competitive impact of a proposed acquisition in the U.S. and certain foreign countries, September 1991.

"Public Disclosure of Bids and Bidders," (with M. Bidwell and H. Nalbantian), prepared for New York Telephone Company, June 1991.

"Hospital Rate Regulation in Maryland: The Effect on Howard County General Hospital," (with C. Groszer and L. Nordgulen), prepared to help a client identify methodological and statistical problems with the approach to hospital rate setting in Maryland, April 1989.

"Bidding Theory and the Baseball Player Market," prepared for a client concerned about compensation issues in professional sports, November 1988.

"The Bulk Power Coordination Services Market in Northern California: A Competitiveness Assessment," (with M. Rosenzweig and L. Nordgulen), prepared for a U.S. investor-owned utility, July 1988.

"An Analysis of the Westinghouse/ASEA-Brown Boveri Joint Ventures," prepared for a client concerned about combinations of firms in electric equipment markets, July 1988.

TRANSFER PRICING STUDIES

Dr. Rozek has prepared numerous transfer pricing studies under U.S., OECD, and foreign transfer pricing guidelines. His work has involved valuing both tangible and intangible property. The associated industries include: agricultural chemicals, automobiles, bicycles, flavors and fragrances, medical devices, pharmaceuticals, professional services, soft drinks, and surgical instruments.